Drugs / CH505TF gp120
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05182125 | Nov 2021 → Aug 2023 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT04607408 | Nov 2020 → Jul 2024 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CH505TF gp120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05182125 ↗ |
| Modality | Protein / enzyme biologic | “This study evaluated the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.” NCT04607408 ↗ |
| Route | Intramuscular | “administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6.” NCT05182125 ↗ |